Doctor of Osteopathy Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Tal Klatchko

Critical Care Medicine Charleston, SC Doctor of Osteopathy

NPI 1760630388 CMS profile 352801

2097 Henry Tecklenburg Dr, Suite 305 West, Charleston, SC 29414

Open in the dashboard

General payments

$1,299

82 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Tal Klatchko of Charleston, SC is reported in the CMS Open Payments database as having received $1,299 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $166 11
2019 General $1,133 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tal Klatchko
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Tal Klatchko were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Tal Klatchko Critical Care Medicine median Middle half National median
2019 $1,133 $149 $51–$535 $163
2020 $166 $110 $30–$325 $114
2021 $0 $125 $34–$403 $132
2022 $0 $157 $49–$582 $149
2023 $0 $162 $56–$621 $160
2024 $0 $168 $53–$634 $164
2025 $0 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. AstraZeneca Pharmaceuticals LP $222 14 payments
  2. GlaxoSmithKline, LLC. $220 16 payments
  3. Genentech USA, Inc. $168 10 payments
  4. Novartis Pharmaceuticals Corporation $147 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $146 8 payments
  6. Sunovion Pharmaceuticals Inc. $122 11 payments
  7. Genzyme Corporation $83 4 payments
  8. Mallinckrodt Enterprises LLC $43 3 payments
  9. Regeneron Healthcare Solutions, Inc. $42 2 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $21 1 payment
  11. Other $85 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $1,299 82 payments
Products named General payments · program years 2019–2020
  1. SYMBICORT $166 10 payments
  2. Xolair Immunology $158 9 payments
  3. XOLAIR Respiratory $147 8 payments
  4. LONHALA MAGNAIR $122 11 payments
  5. FASENRA $103 5 payments
  6. DUPIXENT $103 5 payments
  7. OFEV $102 5 payments
  8. Esbriet $62 4 payments
  9. TRELEGY ELLIPTA $62 4 payments
  10. NUCALA $61 4 payments
  11. Other $355 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$39,362

Medicare's payments for the services billed

Medicare patients

147

Average age 74

Services billed

305

84 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 55%
Diabetes 54%
Ischemic heart disease 54%
Chronic kidney disease 53%
Atrial fibrillation 52%
Arthritis 48%
COPD 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record